The current study suggests that intravenous injection of MSCs into rabbits with chemotherapy-induced ovarian damage improved ovarian function. MSCs accomplish this function by direct differentiation into specific cellular phenotypes and by secretion of VEGF, which influence the regeneration of the ovary.
Objective: To evaluate the efficacy and safety of metformin use in rheumatoid arthritis (RA) patients receiving conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs).Methods: A prospective, randomized, controlled, single blinded, study was carried on 66 RA patients with moderate and high disease activity state, receiving csDMARDs. Patients were simply randomized to receive either metformin 850 mg twice daily (Metformin group, n = 33), or placebo twice daily (Control group, n = 33) in addition to their stable anti-rheumatic regimen and followed up for 6 months. Serum C-reactive protein (CRP), disease activity of 28 joints based on CRP (DAS-28-CRP), and quality of life (QOL) were evaluated at baseline and then every 3 months. Moreover, serum adiponectin was assessed at baseline and after 6 months.Results: Sixty patients completed the study. Drop out was due to intolerance to metformin side effects (n = 3) and non-compliance (n = 3). Metformin significantly decreased CRP levels and DAS-28-CRP after 6 months compared to the control group (p-value <0.001). A significant improvement in QOL of metformin group was observed as early as after 3 months (p-value = 0.006) with a continued improvement observed at 6 months (p-value <0.001) compared to the control group. Despite the significantly higher serum adiponectin in the metformin group at baseline, it was significantly reduced after 6 months in the metformin group with median percent change of −63.49% compared to the significant increase in the control group with median percent change of 92.40%.Conclusion: Metformin significantly improved inflammation, disease severity, and QOL in RA patients with high safety profile.Clinical Trial Registration: Clinical-Trials.gov, identifier [NCT08363405].
Background: The aim of this study is to assess ovarian cancer epidemiology and detect its prognostic factors in Assuit, Egypt.Methods: This retrospective study was performed between January 2010 and December 2015, on all cases attending to Obstetrics and Gynecology Outpatient Clinic in all central hospitals in Assiut. 378 females (≥40 years old) came to Obstetrics and Gynecology Outpatient Clinic from January 2010 to December 2015. Inclusion criteria: All females (≥40 years old), history of current acute or chronic pelvic pain, mass; fixed, hard consistency, history of previous similar condition.Results: Mean age for whole ovarian cancer cases in this study was 56.44±10.08 (range, 40-85). Nulliparity was found in one case (0.3%), while multiparity was found in 252 cases (66.7%). Grand multiparity was found in 113 cases (29.9%). Twelve cases (3.2%) were virgin. Vaginal ultrasound can find all ovarian cancer cases. Regarding the serum levels of the tumor biomarker, CA-125, the average level of CA-125 is 300-1000 U/ml with 34.9% of cases had readings below to 300-1000 U/ml and 6.1% of cases had readings above to this average level. Regarding treatment, treatment combining surgery with chemotherapy was the main line of management in present study (46.3%). About 33.3% of cases underwent surgery, while only 18.3% took the chance of chemotherapy. Eight cases (2.1%) had no treatment.Conclusions: Epithelial ovarian cancer is a lethal disease. The age incidence of ovarian cancer in present patients is ten years younger than what is re¬ported in US SEER data and other Western countries. CA-125 level and ultrasonography are increasing the rate of suspicious for diagnosis of malignant tumors.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.